Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Semaglutide (Ozempic, Wegovy): GLP-1 receptor agonist 31-amino acid peptide Position 2: Aib substitution Position 20: Lys acylated with a C18 fatty diacid via a Glu-(AEEA-AEEA) linker Position 28: Arg substitution Tirzepatide (Mounjaro, Zepbound): Dual GIP/GLP-1 receptor agonist 39-amino acid peptide: Position 2 and 13: Aib substitution Position 20: Lys acylated with a C20 fatty diacid via a Glu-(AEEA-AEEA) linker Position 30-39: Amino acid sequence from exenatide Retatrutide: Triple GLP-1/GIP/GCG receptor agonist 39-amino acid peptide: Position 2 and 20: Aib substitution Position 13: Leucine modified with an -methyl group (2-Methylleucine) Position 17: Lys acylated with a C20 fatty diacid via a Glu-(AEEA) linker Position 30-39: Amino acid sequence from exenatide Semaglutide and Tirzepatide are widely available and well-studied, while Retatrutide's long-term effectiveness and safety profile are still being investigated in clinical trials
There is currently no NICE technology appraisal guidance on retatrutide, as the drug has not yet completed the regulatory and appraisal process
Laboratory testing may be individualized based on your medical history and risk factors and could include metabolic panel, lipid profile, and hemoglobin A1c to establish baseline values and identify any underlying conditions requiring attention
The copper component proves important for collagen and elastin synthesis
For type 2 diabetes patients with significant insulin resistance and obesity, tirzepatide may address the root metabolic dysfunction in ways that exogenous insulin cannot
